Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus johnsonii
- Development stage
- Unknown
- Lead developer
- Sir Run-Run Shaw Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus johnsonii is a species of lactic acid bacteria utilized as a probiotic and live biotherapeutic product. It is currently being evaluated in clinical trials, primarily by the Sir Run Run Shaw Hospital and Zhejiang University, for the treatment of mild active ulcerative colitis in elderly patients and for improving ovarian function in perimenopausal women. The therapeutic effects of L. johnsonii are largely mediated through its modulation of the gut microbiota and the production of bioactive metabolites. In preclinical studies, it has demonstrated anti-atherosclerotic properties by increasing butyrate levels, which activate G-protein coupled receptors (GPR41, GPR43, and GPR109A) to inhibit macrophage pyroptosis. Additionally, it exhibits bile salt hydrolase activity, converting conjugated bile acids into chenodeoxycholic acid (CDCA), which promotes apoptosis in colorectal cancer cells by inducing mitochondrial dysfunction and oxidative stress.
- Other names
- L. johnsonii
02
Targets
FFAR2FFAR3 (Free fatty acid receptor 3)HCAR2 (Hydroxycarboxylic acid receptor 2)
Beyond the preview
Go deeper on lactobacillus johnsonii.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus johnsonii.